SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: In vitro studies revealed that PPARγ agonists reduce BCR::ABL1 kinase inhibition by imatinib in BCR::ABL1+ cell lines and OCT-1 activity in diagnosis CML MNCs [96].